You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 22, 2024

PANHEPRIN Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Panheprin patents expire, and what generic alternatives are available?

Panheprin is a drug marketed by Hospira and is included in one NDA.

The generic ingredient in PANHEPRIN is heparin sodium. There are seventy-seven drug master file entries for this compound. Twenty-two suppliers are listed for this compound. Additional details are available on the heparin sodium profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Panheprin

A generic version of PANHEPRIN was approved as heparin sodium by HOSPIRA on April 28th, 1983.

  Subscribe

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for PANHEPRIN?
  • What are the global sales for PANHEPRIN?
  • What is Average Wholesale Price for PANHEPRIN?
Summary for PANHEPRIN
US Patents:0
Applicants:1
NDAs:1
DailyMed Link:PANHEPRIN at DailyMed
Drug patent expirations by year for PANHEPRIN

US Patents and Regulatory Information for PANHEPRIN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hospira PANHEPRIN heparin sodium INJECTABLE;INJECTION 005264-004 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hospira PANHEPRIN heparin sodium INJECTABLE;INJECTION 005264-008 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hospira PANHEPRIN heparin sodium INJECTABLE;INJECTION 005264-006 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hospira PANHEPRIN heparin sodium INJECTABLE;INJECTION 005264-007 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
Hospira PANHEPRIN heparin sodium INJECTABLE;INJECTION 005264-009 Approved Prior to Jan 1, 1982 DISCN No No ⤷  Subscribe ⤷  Subscribe ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

PANHEPRIN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Heparin: A Comprehensive Analysis

Introduction

Heparin, a crucial anticoagulant, plays a vital role in preventing blood clotting and is widely used in various medical applications. The global heparin market is experiencing significant growth, driven by several key factors. Here, we delve into the market dynamics and financial trajectory of heparin, highlighting its current state, growth drivers, and future projections.

Current Market Size and Growth Projections

The global heparin market was valued at USD 7.56 billion in 2023 and is projected to grow at a compound annual growth rate (CAGR) of 2.7% from 2024 to 2030, reaching USD 9.03 billion by 2030[1][4].

Growth Drivers

Several factors are driving the growth of the heparin market:

Increasing Prevalence of Chronic Diseases

The rising incidence of chronic diseases such as cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes is a major driver. According to the WHO, noncommunicable diseases (NCDs) cause about 41 million deaths annually, with cardiovascular diseases accounting for 17.9 million of these deaths[1].

Growing Demand for Whole Blood and Blood Components

The increasing demand for whole blood and blood components transfusion is another significant factor. This demand is fueled by the growing need for surgical procedures and the management of various medical conditions[1].

Increasing Geriatric Population

The global geriatric population is on the rise, and this demographic is more prone to chronic diseases that require anticoagulant therapy. This demographic shift is expected to boost the demand for heparin[1].

High Usage of Plasma in the Pharmaceutical Industry

The pharmaceutical industry's high usage of plasma, a key component in heparin production, further drives the market growth[1].

Regional Outlook

North America

North America dominated the heparin market in 2023, accounting for 38.6% of the global market share. This dominance is attributed to rising patient awareness, high disease burden, proactive government measures, technological advancements, and improvements in healthcare infrastructure. The presence of key players in this region also significantly contributes to market growth[1][4].

Asia Pacific

The Asia Pacific region is expected to register the highest CAGR during the forecast period due to the increasing need for anticoagulants, a strong potential patient population, and significant healthcare expenditure. The growing applications of low molecular weight heparin (LMWH) in this region are also driving market growth[4].

Source Outlook

Porcine vs. Bovine Heparin

The porcine segment accounted for the largest revenue share of 90.0% in 2023. Porcine heparin is preferred due to its higher anticoagulant activity and ease of neutralization in adverse situations compared to bovine heparin[1].

Route of Administration and Application Outlook

Intravenous and Subcutaneous Administration

Heparin is administered through intravenous and subcutaneous routes. These methods are crucial in preventing deep vein thrombosis, pulmonary embolism, and managing conditions during surgeries[4].

Applications in Various Medical Conditions

Heparin is used in treating various conditions, including venous thromboembolism, atrial fibrillation, renal impairment, and coronary artery disease. The versatility of heparin in different medical applications further supports its market growth[1].

End-Use Outlook

Inpatient Segment

The inpatient segment is expected to register a significant CAGR from 2024 to 2030. This growth is driven by advancements in wound healing equipment, leading to quicker patient recovery times, and effective insurance and reimbursement policies that increase hospital visits[1].

Key Players and Competitive Landscape

Major players in the heparin market include Pfizer Inc., LEO Pharma A/S, Dr. Reddy’s Laboratories Ltd., GlaxoSmithKline plc, Sanofi, Aspen Holdings, Fresenius SE & Co. KGaA, B. Braun Medical, Inc., and Sandoz (Novartis AG). These companies are driving market growth through new product launches, partnerships, and significant R&D initiatives[1][4].

Challenges and Opportunities

Supply Chain Disruptions and Product Contamination

The heparin market has faced challenges such as product contamination and supply chain disruptions. However, the critical nature of heparin in medical treatments has ensured its continued demand despite these issues[4].

Increasing R&D Initiatives

The increasing focus on research and development, particularly for synthetic heparin, is expected to escalate trade opportunities and drive market growth. New product launches and partnerships are also anticipated to support the market's expansion[4].

Impact of COVID-19

The COVID-19 pandemic had a positive impact on the heparin market, as the drug was in high demand for treating certain chronic disorders. Although the demand is expected to slow down in post-pandemic years, the importance of heparin remains, ensuring steady growth prospects[4].

Financial Trajectory

The financial trajectory of the heparin market is promising, with steady growth projected over the next several years. Here are some key financial highlights:

  • 2023 Market Size: USD 7.56 billion[1].
  • 2024 Market Size: USD 7.72 billion[1].
  • 2030 Market Size: USD 9.03 billion, growing at a CAGR of 2.7% from 2024 to 2030[1].
  • 2032 Market Size: Projected to reach USD 14.45 billion, growing at a CAGR of 4.4% from 2024 to 2032[4].

Key Takeaways

  • The global heparin market is driven by the increasing prevalence of chronic diseases, growing demand for whole blood and blood components, and the high usage of plasma in the pharmaceutical industry.
  • North America dominates the market, but the Asia Pacific region is expected to show the highest CAGR.
  • Porcine heparin is the preferred source due to its higher anticoagulant activity.
  • The inpatient segment is expected to grow significantly due to advancements in healthcare and effective insurance policies.
  • Major players are driving growth through new product launches and R&D initiatives.

Frequently Asked Questions

Q: What is the current market size of the global heparin market? A: The global heparin market was valued at USD 7.56 billion in 2023[1].

Q: What is the projected CAGR of the global heparin market from 2024 to 2030? A: The global heparin market is projected to grow at a CAGR of 2.7% from 2024 to 2030[1].

Q: Which region dominates the global heparin market? A: North America dominated the global heparin market in 2023, accounting for 38.6% of the global market share[1].

Q: What are the primary sources of heparin, and which is more preferred? A: The primary sources of heparin are porcine and bovine. Porcine heparin is more preferred due to its higher anticoagulant activity and ease of neutralization[1].

Q: What are the key factors driving the growth of the heparin market? A: The key factors include the increasing prevalence of chronic diseases, growing demand for whole blood and blood components, increasing geriatric population, and high usage of plasma in the pharmaceutical industry[1].

Sources

  1. Grand View Research - Heparin Market Size, Share & Growth Analysis Report, 2030
  2. Market Research Intellect - Global IDO inhibitor Market Size, Scope And Forecast Report
  3. Business Research Insights - Enoxaparin Sodium Market Size, Share, Growth To 2032 | Report
  4. Fortune Business Insights - Heparin Market Size, Share & Global Forecast Report [2030]

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.